A Phase 1, Open-label, Randomized, 2-panel, 4-way Crossover Study in Healthy Adult Subjects to Assess the Rilpivirine Relative Bioavailability Compared to the 25-mg Oral Tablet and the Food Effect Following Single Dose Administration of Oral Pediatric Formulation Candidates
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 09 Jun 2016 Status changed from recruiting to completed.
- 27 Nov 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 01 Oct 2015 New trial record